Black Rock Inc. Aadi Bioscience, Inc. Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Aadi Bioscience, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 1,041,006 shares of AADI stock, worth $1.99 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,041,006

Previous 1,081,631 3.76%

Holding current value

$1.99 Million

Previous $2.18 Million 11.49%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$1.59 - $2.44 $64,593 - $99,125	-40,625 Reduced 3.76%	1,041,006 $2.44 Million
Q4 2023 Feb 13, 2024	BUY	$1.97 - $5.41 $149,375 - $410,213	75,825 Added 7.54%	1,081,631 $2.18 Million
Q3 2023 Nov 13, 2023	SELL	$4.84 - $7.13 $54,779 - $80,697	-11,318 Reduced 1.11%	1,005,806 $4.87 Million
Q2 2023 Aug 11, 2023	BUY	$6.84 - $8.56 $964,159 - $1.21 Million	140,959 Added 16.09%	1,017,124 $6.96 Million
Q1 2023 May 12, 2023	SELL	$6.85 - $13.0 $107,531 - $204,074	-15,698 Reduced 1.76%	876,165 $6.34 Million

Q4 2022 Feb 13, 2023	BUY	$11.99 - $14.5 $399,998 - $483,734	33,361 Added 3.89%	891,863 $11.4 Million
Q3 2022 Nov 14, 2022	SELL	$12.03 - $14.22 $531,425 - $628,168	-44,175 Reduced 4.89%	858,502 $12.1 Million
Q2 2022 Aug 12, 2022	BUY	$11.57 - $17.92 $6.86 Million - $10.6 Million	592,550 Added 191.07%	902,677 $11.1 Million
Q1 2022 May 12, 2022	BUY	$16.65 - $24.97 $9,540 - $14,307	573 Added 0.19%	310,127 $5.26 Million
Q4 2021 Feb 10, 2022	BUY	$19.32 - $29.02 $5.67 Million - $8.51 Million	293,304 Added 1804.95%	309,554 $7.48 Million
Q3 2021 Nov 09, 2021	BUY	$25.52 - $41.85 $414,700 - $680,062	16,250 New	16,250 $478,000

Others Institutions Holding AADI

# of Institutions

Shares Held

13.7M

Call Options Held

4.9K

Put Options Held

700

View Full List

About Aadi Bioscience, Inc.

Ticker AADI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,016,800
Market Cap $40.1M
Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...

More about AADI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account